• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

    12/5/22 6:47:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NRXP alert in real time by email
    • Extensive global pharmaceutical leadership experience in clinical development, operations, and medical affairs
    • Focused psychiatry practice expert in PTSD, Affective Disorders and Schizophrenia
    • Proven track record in research as an investigator and academic grant-funded researcher
    • Visiting Scholar at Stanford University, Center for Precision Mental Health and Wellness
    • Former roles at Boehringer Ingelheim and Pendulum Therapeutics

    RADNOR, Pa., Dec. 5, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced the appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP as Senior Vice President, Clinical Development and Medical Affairs.  She will lead the Company's clinical development program and provide medical oversight across all indications. Dr. Carretta will report to the Chief Executive Officer and Director. 

    Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP

    NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

    "The NRx team is excited to have attracted a clinician with deep experience as an investigator.  Dr. Carretta's wealth of knowledge will help drive our mission to develop a first-in-class lifesaving drug for suicidal depression and PTSD.  She has invaluable experience in both front-line care and corporate drug development that will benefit both patients and shareholders.", said Stephen Willard, Chief Executive Officer, and Director, NRx Pharmaceuticals.

    Dr. Carretta has extensive leadership experience in the pharmaceutical industry, developing and executing strategies in medical, clinical scientific and regulatory affairs as well as hiring, developing, and managing diverse medical science and clinical teams globally.  She brings with her an extensive network of key opinion leaders, health care providers and researchers worldwide.

    Dr. Carretta is the co-founder and managing partner at C&G Holdings, LLC and most recently worked for Boehringer Ingelheim Pharmaceuticals as the Executive Director, Therapeutic Area Head for Clinical Development and Medical Affairs leading the CNS and Ophthalmology areas. Prior to this role, Dr. Carretta served as the Vice President, Medical and Scientific Affairs at Pendulum Therapeutics.

    Prior leadership roles at Juul Labs included developing infrastructure and strategies which supported the company's consumer device and her work for Novartis contributed to medical excellence for Cosentyx®, Ilaris®, Entresto® and Kisquali®, with Bayer Pharmaceuticals for The Betaconnect™ autoinjector used with Betaseron®, and with Teva Pharmaceuticals for Adasuve®.

    In addition to her experience in the pharmaceutical industry, Dr. Carretta has acted as an investigator for numerous clinical trials and has worked extensively in clinical practice both in general and forensic psychiatry, and in academia as a funded researcher.

    Dr. Carretta holds a doctorate degree in Nursing from Vanderbilt University and both master's and bachelor's degrees in Nursing from Rutgers, The State University of New Jersey.  She is nationally board certified as an APN-BC, AHN-BC & PMHNP. Dr. Carretta is a current visiting scholar at Stanford University, Center for Precision Mental Health and Wellness.

    About NRx Pharmaceuticals

    NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company's lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's NMDA receptor and is being investigated in a Phase 3 trial under a Food and Drug Administration ("FDA") Special Protocol Agreement and Breakthrough Therapy Designation in patients with bipolar depression and acute suicidal ideation, an indication for which the only approved treatment is electroshock therapy. NRx Pharmaceuticals has also initiated a Phase 2b clinical trial in patients with Sub-Acute Suicidality, potentially a substantially broader indication. The Breakthrough Therapy Designation and Special Protocol Agreement were awarded by the FDA based on the Company's prior STABIL-B trial that demonstrated substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine.

    Cautionary Note Regarding Forward-Looking Statements

    This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management. 

    The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.

    CORPORATE CONTACT

    Molly Cogan

    Sr. Director, Global Communications

    [email protected]

    INVESTOR RELATIONS

    Suzanne Messere

    Investor Relations

    [email protected]

    (PRNewsfoto/NRx Pharmaceuticals)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-the-appointment-of-carrie-m-carretta-phd-apn-bc-ahn-bc-pmhnp-senior-vice-president-of-clinical-development-and-medical-affairs-301694310.html

    SOURCE NRx Pharmaceuticals, Inc.

    Get the next $NRXP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NRXP

    DatePrice TargetRatingAnalyst
    4/2/2025$18.00Buy
    BTIG Research
    More analyst ratings

    $NRXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on NRx Pharmaceuticals with a new price target

      BTIG Research initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      4/2/25 8:51:11 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Abrams Michael S

      4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

      2/11/25 5:00:05 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman and Chief Scientist Javitt Jonathan C bought $46,800 worth of shares (40,000 units at $1.17), increasing direct ownership by 90% to 84,634 units (SEC Form 4)

      4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

      12/18/24 8:27:36 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Abrams Michael S

      3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

      11/22/24 1:44:01 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

      Cohen and Associates is a highly respected neuropsychiatry clinic in western FloridaCohen to serve as foundational clinic in the Sarasota - Bradenton area of FloridaAcquisition expected to be immediately accretive to revenue and EBITDAMIAMI, June 26, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced the signing of a binding Letter of Intent (the "LOI") to purchase a 49% interest in Cohen and Associates, LLC ("Cohen"), founded by Dr. Rebecca Cohen.  Cohen is expected to serve as a foundational clinic for HOPE

      6/26/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IBN Initiates Coverage of NRx Pharmaceuticals Inc.

      AUSTIN, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- via IBN – NRx Pharmaceuticals Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts. NRx Pharmaceuticals is advancing its patented NMDA receptor modulation platform through two investigational drugs: NRX-100 (preservative-free ketamine) and NRX-101 (D-cycloserine/lurasidone). These therapies have received FDA Fast Track and Breakthrough Therapy Designations, respectively, and target critical unmet needs in mental health—specifically suicidal depression and PTSD—for which no F

      6/24/25 8:30:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

      Company has applied for new Commissioner's National Priority Vouchers (CNPV) for NRX-100. Continues to anticipate decisions on drug approval by year-end 2025Application under CNPV program is accretive to already-filed Abbreviated New Drug Application (ANDA) for preservative-free ketamine, with proprietary formulation under priority review requestCompany has received and complied with FDA information request for updated drug ingredient and label information on NRX-100Company has previously filed full Chemical Manufacturing and Controls (CMC) information for NRX-100 with FDA and has reported stability and sterility data sufficient to anticipate three-year room temperature shelf life for preser

      6/23/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    SEC Filings

    See more
    • SEC Form RW filed by NRX Pharmaceuticals Inc.

      RW - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

      6/24/25 5:02:51 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by NRX Pharmaceuticals Inc.

      S-3 - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

      6/20/25 4:37:54 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NRX Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

      6/9/25 12:16:02 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman and Chief Scientist Javitt Jonathan C bought $46,800 worth of shares (40,000 units at $1.17), increasing direct ownership by 90% to 84,634 units (SEC Form 4)

      4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

      12/18/24 8:27:36 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

      SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

      9/13/22 4:47:33 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by NRX Pharmaceuticals Inc. (Amendment)

      SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

      6/17/22 5:00:47 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

      SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

      6/3/22 3:59:15 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    Leadership Updates

    Live Leadership Updates

    See more
    • HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

      Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwideKadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this spaceDr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPEMIAMI, May 13, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP), a clinic

      5/13/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.

      WILMINGTON, Del., Jan. 15, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., a development stage medical and technology driven company and wholly owned subsidiary of NRx, today announced the appointment of Mr. Michael Taylor and Ms. Anita Nunes as Member and Observer of its Board of Directors, respectively.  Ms. Nunes is also to be appointed to the Board of Directors of Hope Therapeutics, Inc. Michael Taylor brings over 25 years of experience in global cr

      1/15/25 8:02:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel

      "'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay GuptaDavid Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry fieldKadima Neuropsychiatry Institute identified as planned HOPE Flagship Clinic pending acquisition closingDr. Feifel is expected to join HOPE as Chief Medical Innovation OfficerMIAMI, Jan. 14, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (NASDAQ:NRXP), today alerted investors that Kadima Neuropsychiatry Institute's Founder David Feifel, MD PHD was fea

      1/14/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRXP
    Financials

    Live finance-specific insights

    See more
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholdersIn January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional investor on favorable terms to the Company; expected to provide sufficient cash to support operations through the end of 2025. Deployed capital to meet the objectives listed belowNRX-100 (preservative-free IV ketamine) pla

      5/15/25 4:03:00 PM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

      WILMINGTON, Del., May 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2025 financial results after the market closes on Thursday, May 15, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day. A live webcast of the conference call will be av

      5/12/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE

      Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities MIAMI, April 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (NASDAQ:NRXP), today announced signing of a term sheet with a global medical device manufacturer, as anticipated in the Company's recently filed annual report. The investor shares HOPE's vision of providing comprehensive interventional psychiatry treatments to patients around the world. 

      4/3/25 8:03:00 AM ET
      $NRXP
      Biotechnology: Pharmaceutical Preparations
      Health Care